Preclinical evaluation of PAC1 targeting with radiolabeled Maxadilan
Abstract There is an ongoing search for new tracers to optimize imaging of beta cell-derived tumors (insulinomas). The PAC1 receptor, expressed by insulinomas, can be used for targeting of these tumors. Here, we investigated whether radiolabeled maxadilan could be used for insulinoma imaging. Maxadi...
Main Authors: | Lieke Joosten, Maarten Brom, Martin K. H. Schäfer, Otto C. Boerman, Eberhard Weihe, Martin Gotthardt |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2017-05-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-017-01852-8 |
Similar Items
-
Preclinical Evaluation of Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors
by: Maarten Brom, et al.
Published: (2011-03-01) -
First‐in‐human development of a pharmacodynamic biomarker for PAC1 receptor antagonists using intradermal injections of maxadilan
by: Heleen Marynissen, et al.
Published: (2022-08-01) -
Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme
by: Zbynek Novy, et al.
Published: (2019-07-01) -
Dissociation between vasodilation and Leishmania infection-enhancing effects of sand fly saliva and maxadilan
by: Fábio Castro-Sousa, et al.
Published: (2001-10-01) -
Maxadilan prevents apoptosis in iPS cells and shows no effects on the pluripotent state or karyotype.
by: Zhiyi Zhao, et al.
Published: (2012-01-01)